Advances in the treatment of chronic lymphocytic leukaemia

Česká verzia

Authors: P. Obrtlíková ¹; M. Trněný ^1,2
Authors place of work: I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Marek Trněný, CSc. ¹; Ústav hematologie a krevní transfuze Praha, ředitel prof. MU Dr. Marek Trněný, CSc. ²
Published in the journal: Vnitř Lék 2013; 59(7): 632-634
Category:

Summary

Chronic lymphocytic leukemia (CLL) is the most common forms of leukemia in the western world and is characterized by a highly variable clinical course. Some patients live for many years without treatment, whereas other have disease with rapid progression. The treatment of chronic lymphocytic leukemia has achieved extraordinary progress over the last years with the incorporation of monoclonal antibodies and combined chemoimmunotherapy. Despite these therapeutic successes, CLL is still considered to be an incurable disease. Only the allogenic transplantation is potentially curative but it is feasible only for selected group of younger patients without comorbidities. However, elderly and comorbid patients, who represent the majority of CLL population, are not usually able to undergo intensive treatment. The search for new treatment options is therefore still relevant. This review summerizes the current treatment options and newly tested drugs in CLL.

Key words:
chronic lymphocytic leukemia – treatment – new drugs

Zdroje

1. Trneny M, Schwarz J, Pavlik T et al. Improving survival in patients with chronic lymphocytic leukemia – population based study. In: ASH Annual Meeting Abstracts 2011.

2. Goldin LR, Björkholm M, Kristinsson SY et al. Elevated risk of chronic lymphocytic leukemia and other indolent non‑Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 2009; 94: 647– 653.

3. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 96– 103.

4. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute‑ Working Group 1996 guidelines. Blood 2008; 111: 5446– 5456.

5. Eichhorst BF, Busch R, Stilgenbauer S et al. First‑line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382– 3391.

6. Hallek M, Fischer K, Fingerle‑ Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open‑ label, phase 3 trial. Lancet 2010; 376: 1164– 1174.

7. Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079– 4088.

8. Obrtlikova P et al. Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting abstracts 2012; 120: 1790.

9. Smolej L et al. Low‑ Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/ Comorbid Patients with chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/ SLL): Preliminary Results of Project Q‑ Lite by Czech CLL Study Group. ASH Annual Meeting Abstracts 2010; 116: 2466.

10. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti‑CD20 antibody, in patients with relapsed or refractory B‑ cell chronic lymphocytic leukemia: a phase 1– 2 study. Blood 2008; 111: 1094– 1100.